创新药产业趋势已成，进军全球商业化

Industry Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The Chinese innovative drug industry has established a trend towards global commercialization, supported by a pyramid structure of leading and quality enterprises, indicating strong sustainability in industry development [2]. - The underlying logic of the current cycle is that Chinese innovative drugs possess global competitiveness, shifting from domestic sales to international licensing and commercialization, thus opening up commercial space and maturing the ecosystem [2]. - The focus on differentiated mechanisms or high clinical value "good molecules" remains a core interest for international buyers, with early data being crucial for entering licensing windows [2]. Current Situation - The Chinese innovative drug industry is entering a phase of realization, driven by support from capital markets, policies, and talent [3]. - The industry has developed self-sustaining capabilities through business development (BD) licensing and drug commercialization [3]. - Comprehensive policy support for "true innovation" has been established, enhancing the industry's growth [3]. Future Outlook - Continued collaboration among academia, industry, and research will enhance the output of first-in-class (FIC) molecules, with China becoming one of the most efficient countries in the drug development pathway [4]. - Higher innovation levels are expected to further unlock commercial value, indicating a promising future for the industry [4]. Investment Recommendations - Focus on global blockbuster products: companies such as BeiGene, Kelun-Biotech, Innovent Biologics, and others are highlighted as key players [5]. - Attention to global best-in-class (BIC) potential companies, including EdiGene, Zai Lab, and others, is recommended [5]. - Domestic blockbuster products and asset values of companies like Hengrui Medicine and others are also suggested for consideration [5].